ArticleBMC biotechnology2025
Unlocking the antioxidant and antibacterial potential of exopolysaccharides produced by endophytic fungi (Aspergillus fumigatus and Preussia isabellae) isolated from Tanzania's mangroves.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Untapped microbial factories for next-generation therapeutics: Endophytic fungi of medicinal plants.Microbial cell factories · 2026Review
- Lactic acid bacteria fermentation improves the physicochemical properties, bioactivity, and metabolic profiles of lychee pulp.Food chemistry: X · 2026Article
- Endophytic bacteria and fungi as a source of polysaccharides: production and characterization techniques.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The investigation of the exopolysaccharide (EPS) produced by mangrove endophytic fungi is of significant importance. In the present work, EPS produced by endophytic fungi (Aspergillus fumigatus and Preussia isabellae) through submerged fermentation was analyzed. A. fumigatus produced significantly (p < 0.05) higher EPS (AF-EPS) (2.13 ± 0.38 g/L) than that produced by P. isabellae (PI-EPS) (1.04 ± 0.17 g/L). Fourier transform infrared spectra revealed varying degrees of functional groups associated with polysaccharides, thereby verifying the presence of EPS. In both EPS extracts, galactose and glucose were the major monomers detected. The antioxidant activities and anti-bacterial ability of the AF-EPS and PI-EPS were determined via 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assays. Results revealed that AF-EPS and PI-EPS exhibited notable DPPH and ABTS radical scavenging capacities. AF-EPS, depicted higher antioxidant capacity, at a concentration of 5.0 mg/mL, could scavenge 70.92 ± 1.77% DPPH free radical and 53.74 ± 3.03% of ABTS free radical. Moreover, the antibacterial competence of each EPS was evaluated against four pathogenic bacteria using disk diffusion methodology. The bacterial inhibition effect of AF-EPS and PI-EPS on Gram-positive bacteria was greater than that of Gram-negative bacteria. Therefore, these findings suggest that AF-EPS and PI-EPS could be used as potential antioxidant and antibacterial agents for various applications, however, further exploration is necessary to investigate possible applications and the underlying mechanisms of these bioactive EPSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.